Evaluating the safety and technical effectiveness of bilateral facial and trigeminal nerve combing for the treatment of Meige's syndrome

Evaluating the safety and technical effectiveness of bilateral facial and trigeminal nerve combing for the treatment of Meige's syndrome: a first-in-human multiple center clinical trial in China

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033481

Enrollment

Unknown

Registered

2020-06-02

Start date

2020-07-01

Completion date

Unknown

Last updated

2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meige's syndrome

Interventions

Intervention group:bilateral facial and trigeminal nerve combing

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with Meige syndrome with definite diagnosis; 2. Patients who can tolerate general anesthesia; 3. Patients who can describe their subjective feelings; 4. Patients aged 40-75 years; 5. Patients who are not effective after botulinum toxin treatment; 6. Patients willing to participate in the clinical study; 7. The subjects with normal structure and function of facial nerve and trigeminal nerve.

Exclusion criteria

Exclusion criteria: 1. Patients with cognitive impairment, dementia and severe mental illness; 2. Patients with other dystonia; 3. Patients with a history of alcohol and drug abuse; 4. Patients with intracranial tumor, trauma and other secondary factors; 5. Patients who had received botulinum toxin treatment within 3 months before admission.

Design outcomes

Primary

Measure	Time frame
BFMDRS grade;	—

Countries

China

Contacts

Public ContactShiting Li

Xinhua Hospital Affiliated to School of Medicine, Shanghai Jiaotong University

lishiting@xinhuamed.com.cn+86 21-25078001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026